BACKGROUND: Bupropion is used to treat depression during pregnancy. However, its usefulness as a smoking cessation aid for pregnant women is not fully known. OBJECTIVE: The objective of the study was to evaluate the preliminary efficacy of bupropion sustained release for smoking cessation during pregnancy. STUDY DESIGN: We conducted a randomized, prospective, doubleblind, placebo-controlled, pilot trial. Pregnant women who smoked daily received individualized behavior counseling and were randomly assigned to a 12 week, twice-a-day treatment with 150 mg bupropion sustained release or placebo. The primary study objectives were to determine whether bupropion sustained release reduces nicotine withdrawal symptoms on the quit date and during the treatment period compared with placebo and whether it increases 7 day point prevalence abstinence at the end of the treatment period and at the end of pregnancy. RESULTS: Subjects in the bupropion (n ¼ 30) and placebo (n ¼ 35) groups were comparable in age, smoking history, number of daily smoked cigarettes, and nicotine dependence. After controlling for maternal age and race, bupropion sustained release reduced cigarette cravings (1.5 AE 1.1 vs 2.1 AE 1.2, P ¼ .02) and total nicotine withdrawal symptoms (3.8 AE 4.3 vs 5.4 AE 5.1, P ¼ .028) during the treatment period. Administration of bupropion sustained release reduced tobacco exposure, as determined by levels of carbon monoxide in exhaled air (7.4 AE 6.4 vs 9.1 AE 5.8, P ¼ .053) and concentrations of cotinine in urine (348 AE 384 ng/mL vs 831 AE 727 ng/mL, P ¼ .007) and increased overall abstinence rates during treatment (19% vs 2%, P ¼ .003). However, there was no significant difference in 7 day point prevalence abstinence rates between the 2 groups at the end of medication treatment (17% vs 3%, P ¼ .087) and at the end of pregnancy (10% vs 3%, P ¼ .328). CONCLUSION: Individual smoking cessation counseling along with the twice-daily use of 150 mg bupropion sustained release increased smoking cessation rates and reduced cravings and total nicotine withdrawal symptoms during the treatment period. However, there was no significant difference in abstinence rates between groups at the end of medication treatment and at the end of pregnancy, likely because of the small sample size. A larger study is needed to confirm these findings and to examine the potential benefit/ risk ratio of bupropion sustained release for smoking cessation during pregnancy.
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D
espite the well-known obstetrical, fetal, and developmental complications associated with cigarette smoking, 15 .9% of all pregnant women continue to smoke throughout pregnancy. 1 Behavioral interventions are only modestly effective in helping pregnant women quit smoking. 2, 3 Smokingcessation medications increase the chance of quitting smoking in men and nonpregnant women, 2 and they could also be used to reduce cigarette cravings and withdrawal and to enhance quit rates during pregnancy.
Bupropion sustained release (SR), an antidepressant, is commonly used to promote smoking cessation in males and nonpregnant females. 4 The effectiveness of bupropion (Zyban, Wellbutrin) as a smoking cessation aid for pregnant women was suggested in a prospective observational study, in which pregnant smokers receiving bupropion 150 or 300 mg daily had higher quit rates than controls. 5 Based on this information, we conducted a randomized, prospective, double-blind, placebo-controlled, pilot trial of the preliminary efficacy of bupropion SR in combination with behavioral counseling for smoking cessation during pregnancy. The primary study objectives were to determine the following: 1) whether bupropion SR reduces nicotine withdrawal symptoms on the quit date and during medication treatment and 2) whether bupropion SR increases 7 day point prevalence abstinence at the end of medication treatment and at the end of pregnancy compared with placebo. Secondary objectives included the assessment of bupropion SR on overall quit rates during treatment and on adverse effects during pregnancy when compared with placebo.
Materials and Methods
Prior to implementation, the study protocol was reviewed and approved by The University of Texas Medical Branch (UTMB) Institutional Review Board and was registered on Clinicaltrials.gov (ClinicalTrials.gov, identifier NCT01390246). An independent Data Safety and Monitoring Board reviewed ongoing trial data, including efficacy rates and serious adverse events (SAEs) through the study.
Recruitment
Pregnant smokers were recruited through the UTMB Department of Obstetrics and Gynecology clinics and the UTMB Regional Maternal Child Health Program clinics. Referrals from heath care providers were also accepted. In addition, the study was advertised 
Inclusion and exclusion criteria
Inclusion criteria were as follows: women !18 years of age between 13 and 30 weeks' gestation, smoking !10 cigarettes per day (CPD) prior to pregnancy and 5 CPD for the preceding 7 days, English or Spanish speaking, and having the intent to carry to term.
Exclusion criteria were current illicit drug or alcohol abuse or dependence; multiple gestation; treatment for a psychiatric disorder within the last 6 months; unstable medical problems (pregnancy-induced hypertension [blood pressure (BP) >140/90 mg Hg], preeclampsia, threatened abortion, hyperemesis gravidarum); known fetal congenital abnormality; seizure disorder; use of psychotropic medication; use of medication known to lower the seizure threshold; anorexia/bulimia; a personal history of closed head trauma with >30 minutes of loss of consciousness or amnesia or resulting in a skull fracture or subdural hematoma/brain contusion; current use of any other smoking cessation treatment; and current use of methadone.
Consent and randomization
Prior to participation in the study, all subjects agreed and signed the institutional review boardeapproved informed consent. To ensure comparability of subjects in the treatment groups, we used the urn randomization method. 6 The groups were balanced for 2 variables: gestational age at study entry and number of CPD. Subjects, primary investigators, and research nurses were blinded to pharmacotherapy group assignment.
Study design
The study protocol consisted of 10 visits: first, enrollment, randomization, and study medication dispensation; second, the scheduled quit date; third to sixth, medication therapy progress assessment; seventh, the end of pregnancy (36e38 weeks' gestation); and eighth to tenth, 1, 3, and 6 month postnatal assessments of abstinence ( Figure 1 ). Participants received either bupropion SR or matched placebo orally once daily for 3 days followed by twice daily for a total medication treatment of 12 weeks.
The University of Iowa Pharmaceuticals (Iowa City, IA) was contracted for production, labeling, and bottling of the active drug and placebo tablets. To confirm patients' proper use of medication, participants were asked to keep a daily diary of the number of pills taken. Subjects then returned the study drug bottles at the next study visit to the research nurse who performed pill counts for compliance records. Compliance to study medication was also biochemically confirmed as described in the following text in the Biochemical measures section.
Both groups received behavioral interventions, which included 35 minute counseling sessions at each of the first 2 visits (enrollment and on the quit day) and 10 minutes of smoking cessation counseling at subsequent visits. Counseling sessions were delivered by a research nurse using a motivational interviewing approach, 7, 8 which was previously shown to be effective in pregnant smokers. 9 
Measures
Prior to the smoking intervention, baseline standardized questionnaires assessed demographics, and smoking history/status as well as medical and obstetrical history. Additional questionnaires assessed the confidence and motivation to quit, concerns about excessive weight gain, and confidence in bupropion as a smoking cessation aid. The questionnaires were based on the clinical trials published previously, 10, 11 and each parameter was measured using a 5 point scale (1, least likely/mostly disagree, 5, highly likely/mostly agree). Nicotine dependence was assessed using the 6 item Fagerstrom Test of Nicotine Dependence. 12 The Minnesota Nicotine Withdrawal Scale (MNWS) 13 and the Primary Care Evaluation Score 14 questionnaires were completed at every visit, including baseline.
At every visit, a research nurse monitored the smoking status of all subjects (ie, CPD, exhaled carbon monoxide [CO] ) and adverse events (AEs). Exhaled CO was measured using a Vitalograph carbon monoxide monitor (Lenexa, KS) according to the manufacturer's recommendations. A urine sample was collected at each visit and stored at e80 C. AEs, including SAEs, were assessed on all subjects during interviews by the research nurse at each study visit. We monitored for maternal AEs that could be related to bupropion, such as seizures, BP >140/90 mm Hg, headache, insomnia, rhinitis, dry mouth, and anxiety. We defined a priori which AEs would be considered fetal and neonatal SAEs: intrauterine fetal demise, preterm delivery (<34 weeks), clinically suspected fetal growth restriction, congenital malformations, cardiovascular anomalies, low birthweight (<10%), Apgar scores <7 at 5 minutes, and neonatal length of hospital stay >3 days. Research nurses also abstracted data on pregnancy and neonatal outcomes from electronic medical records after delivery.
Biochemical measures
The accuracy of self-reported smoking abstinence during study visits was confirmed by an exhaled CO level of <4 parts per million (ppm) 15, 16 and by urinary cotinine level of <50 ng/mL. 17, 18 Cotinine in urine was quantified using the validated liquid chromatographye mass spectrometry (LC/MS) method 19, 20 ; sample extraction was based on the procedure described by Petersen et al. 21 Patients' compliance to the study medication was confirmed by concentrations of bupropion in urine and its metabolites (hydroxybupropion and threohydrobupropion) using the method reported previously.
22,23
Retention Subjects received phone call reminders prior to each study visit. If a participant missed the appointment, the research staff called to reschedule. If research personnel were unable to reach a subject ajog.org 
Data analysis
The original sample was based on detecting a difference in MNWS symptoms (ie, cigarette craving and total withdrawal scores) between the bupropion and placebo groups as a measure of potential efficacy. The study was powered for 3 outcomes: cigarette cravings, total MNWS withdrawal scores, and quit rates. A previous study of smoking cessation in pregnant women reported a standardized difference of d ¼ 1.0 for cravings and d ¼ 0.6 for total MNWS. 24 In addition, a study of Hurt et al 25 (1997) reported a 45% quit rate among male and nonpregnant female smokers treated with bupropion SR for cessation, whereas a 19% quit rate was observed among those receiving placebo. The initial targeted enrollment of 50 women per group would yield a power of 0.85 with an alpha of 0.05 to detect differences in total MNWS scores, 0.99 power to detect differences in craving scores, and 0.80 power to detect differences in quit rates. However, 2 years after the trial had initiated, the sample size was reestimated because the original calculations were overpowered for some measures and the enrollment into the study was more difficult than expected. Thus, 30 subjects per group was still sufficiently powered (0.80) for the craving score; however, the total MNWS score was powered to 0.65 and the quit rate to 0.60.
Baseline characteristics between groups were compared using a 2 sample Student t test for continuous variables 
Results
Five hundred eleven pregnant women were approached by research nurses to determine their study eligibility. Of these subjects, 200 (39%) did not meet inclusion criteria, 246 subjects (48%) were not enrolled for various reasons (Figure 1 ), and 65 pregnant women (13%) were enrolled in the study. Of the recruited 65 subjects, 30 were randomized to the bupropion group and 35 to the placebo group. Table 1 presents demographic and baseline characteristics of study participants. The average gestational age at enrollment was 18.9 AE 4.5 weeks. Participants reported average smoking of 18 AE 8 CPD prior to pregnancy and 12 AE 8 CPD at enrollment. The distribution of demographic and baseline characteristics was similar in both groups except race/ethnicity (49% white/non-Hispanic in the placebo group vs 77% white/non-Hispanic in the bupropion group, P ¼.011) and age (27.5 AE 6.5 years vs 24.5 AE 5.6 years, P ¼.051).
Demographic and baseline characteristics
Fifty-seven percent of women enrolled had previously tried to quit smoking during their current pregnancy. The average total Fagerstrom Test of Nicotine Dependence and Primary Care Evaluation scores as well as the average scores for motivation and confidence to quit did not differ among study groups ( Table 1 ). The average level of worries about excessive weight gain caused by intervention was not very high (2.4 AE 1.6), and many participants believed that bupropion would be helpful (mean score 3.9 AE 0.8) to them for smoking cessation.
Smoking abstinence
Seven day point prevalence abstinence was defined at each visit as no cigarettes (not even a puff) in the last 7 days, levels of CO in exhaled air <4 ppm, 15, 16 and concentrations of cotinine in urine <50 ng/mL. 17, 18 The point prevalence abstinence rates during the treatment assessment period (visits 2e6) between study groups were significant (2% in the placebo group vs 19% in the bupropion group, P ¼.003, Figure 2 ). There was no significant difference in abstinence rates between the bupropion and placebo groups at the end of medication treatment, visit 6 (17% vs 3%, P ¼.087), and at the end of pregnancy, visit 7 (10% vs 3%, P ¼.328), and during the postpartum period (visits 8e10).
Compared with baseline levels of selfreported cigarette consumption, there was at least a 50% reduction in cigarettes smoked per day during treatment, at the end of pregnancy, and postpartum in both groups (Table 2) . Although this reduction in cigarette consumption was not statistically significant between the groups, exhaled CO and urinary cotinine concentrations during treatment (visits 2e6) were higher in the placebo group than the bupropion group (P ¼.011 and P <.001, respectively, Table 2 ).
There was no significant difference between the groups in total nicotine withdrawal symptoms (P ¼.068) and tobacco cravings (P ¼.08) in the unadjusted analysis; however, after controlling for maternal age and race, these measures were statistically significant between groups, with the placebo groups having greater withdrawal symptoms and craving during treatment (P ¼.028 and P ¼.02, respectively, Table 2 ).
Birth and delivery outcomes
There were no significant differences between treatment groups in birthweight, infant length, head circumferences, Apgar score at 5 minutes, and pH values in arterial and venous cord blood ( Table 3 ). The gestational age (P ¼.058) and Apgar score at 1 minute (P ¼.064), although not statistically significant, trended higher in the bupropion group.
SAEs occurred in 5 subjects in the placebo group and 2 in the bupropion group. In the placebo group, 4 involved an infant stay greater than 3 days (2 cases of premature delivery, one for respiratory distress, and one for hyperbilirubinemia). The other SAE in the placebo group was due to a maternal hospitalization for diabetes management. The two SAEs in the bupropion group involved a subject who developed superimposed preeclampsia requiring delivery at 32 weeks 2 days and an infant with a cord blood pH value of 7.01. Following clinical review, both events were considered unlikely related to the study medication.
Maternal outcomes
There were no differences between the bupropion and placebo groups in body Compliance with study medication and retention
The proportion of adherence to the study medication in the bupropion group was 87.4%, compared with 82% in the placebo group (P ¼.31). Although the majority of subjects in both groups were able to correctly guess which treatment they received (P ¼.049), 33% of subjects in the placebo group believed they received bupropion SR, and 29% of subjects in the bupropion group believed they received placebo.
There was a high rate of early withdrawal from the study; only 20% of all subjects completed the clinical trial (30% of subjects in the bupropion group vs 11% in the placebo group, P ¼.12). There were no differences in education level, number of adults and children in household, annual income, smoking, and psychosocial variables in the subjects who withdrew from the study vs those who stayed in the study. Higher completion rates were observed among subjects who lived with a partner vs those who did not (P ¼.013). In addition, the slightly higher completion rate in the cohort was associated with Hispanic vs non-Hispanic ethnicity (P ¼.07) and part-time (P ¼.08) vs nonor full-time workers (whose completion rates were similar).
Comment
In this randomized, placebo-controlled, pilot study of bupropion SR for smoking cessation during pregnancy, bupropion SR reduced nicotine cravings and withdrawal symptoms compared with placebo and increased overall cessation rates during medication treatment. Abstinence rates were not statistically significant between groups at the end of pregnancy and postpartum, likely because of the small sample size. The medication was relatively well tolerated, and the SAE rate was similar between groups (although numerically lower in the bupropion SR compared with the Rates of confirmed abstinence from smoking (A) and assessment of smoking status in confirmed quitters (B) during treatment period (visits 2e6), at the end of pregnancy (visit 7), and in the postpartum period (visits 8e10). Abstinence was defined as no cigarettes (even a puff) in the last 7 days, levels of CO in exhaled air <4 ppm, and concentration of cotinine in urine less than 50 ng/mL. Five subjects in the bupropion group achieved abstinence during the treatment period. Four of 5 subjects achieved 7 day point prevalence abstinence 1 week after the quit date (visit 3) and 1 subject 7 weeks after the quit date (visit 5). All 5 subjects in the bupropion group remained abstinent up to the last visit during the treatment period (visit 6). In the placebo group, 1 subject achieved 7 day point prevalence abstinence at visit 6, and another subject was abstinent at visit 7. Only 3 of 5 subjects who achieved abstinence during treatment in the bupropion group continued the study after visit 6 (end of treatment period) and remained abstinent at the end of pregnancy (visit 7). If a subject missed a visit, she was counted as abstinent if she met the above-mentioned criteria before and after this visit. All subjects are included at all time points. Missing data are recorded as smoking. ajog.org OBSTETRICS Original Research placebo group). These findings suggest that bupropion SR may be a promising adjunctive medication for smoking cessation during pregnancy. It is noteworthy that we used a conservative estimate for cigarette abstinence, counting those who were lost to follow-up as smokers. It is possible that some of the individuals who quit smoking with bupropion or placebo and were lost to follow-up may have been tobacco free at the end of treatment and after pregnancy.
During the treatment period, bupropion SR significantly reduced smoking as determined by levels of CO in exhaled air and concentrations of cotinine in the urine of pregnant women. The results of our study are in agreement with a previous observational study of bupropion SR effectiveness in pregnancy 5 as well as with the existing literature on nonpregnant smokers showing that, compared with placebo, bupropion can approximately double the chance of smoking cessation success. 25 A significant impact of bupropion SR compared with placebo on measures of cravings and nicotine withdrawal symptoms during treatment was observed. This finding is consistent with other studies showing that bupropion SR reduces cravings for tobacco and signs and symptoms of nicotine withdrawal. 25 It is noteworthy that many of the signs of nicotine withdrawal can also commonly occur during pregnancy (irritability, anxiety, difficulty concentrating, insomnia, restlessness, increased Original Research OBSTETRICS ajog.org appetite, depressed mood, and drowsiness), 26 and use of medications that reduce nicotine withdrawal could be especially beneficial during pregnancy to improve smoking cessation rates. Because the bupropion SR compared with the placebo group had lower overall nicotine withdrawal symptoms (which include insomnia and anxiety) but higher reports of at least 1 episode of insomnia and anxiety during treatment, it seems likely that these 2 symptoms may have been in part due to the medication in the bupropion SR group.
One of the major goals of prenatal management in women who smoke during pregnancy is to decrease the preterm delivery and low birthweight in neonates. Although our study was not powered to detect differences in neonatal outcomes, the difference in gestational age and Apgar score at 1 minute was in favor of the bupropion group.
Previous studies have shown that bupropion results in modest weight loss in patients with depression 27 and hypertension. 28 Our study did not reveal any differences between the bupropion and placebo groups in body weight, systolic and diastolic BP, and pulse rate. SAEs were not significantly different between the groups. One subject in the bupropion group at 32.0 weeks' gestation was diagnosed with superimposed preeclampsia. The association between preeclampsia and antidepressant use during pregnancy has been previously suggested. 29, 30 However, a recent study of an exposure-outcome relationship within a nationwide Medicaid cohort did not find an association between bupropion use during pregnancy and preeclampsia (relative risk, 1.06; 95% confidence interval, 0.91e1.25). 31 There are some limitations to the present study. One of the factors that affected enrollment of eligible subjects to the pilot study is the social stigma associated with both prenatal smoking and prenatal use of medications. It appears that there is a general misperception of risks associated with prenatal smoking and the potential benefit to risk ratios of smoking cessation with bupropion SR. An integrated effort of medical providers who can directly address these issues along with education of eligible women and family members provided via clinic media and printed material should overcome the challenges associated with recruitment in future studies.
A high rate of early withdrawal from the clinical trial was another challenge encountered in this study. Implementation of home visits in future studies could help retain the recruited number of subjects through 10 visits, beginning in pregnancy and following through the postpartum period (up to 6 months after delivery).
The present study provides preliminary evidence that bupropion SR could be beneficial for smoking cessation during pregnancy. This result is encouraging because placebo-controlled trials of nicotine replacement therapy for smoking cessation during pregnancy have not shown increased smoking cessation rates. 32 A large-scale study is warranted to fully examine the efficacy and safety of bupropion SR for smoking cessation during pregnancy. n 
